Embedded Files
Primary Sjogren's syndrome (pSS)
Primary Sjogren's syndrome (pSS)
Autoimmune disease of exocrine glands particularly salivary and lacrimal glands characterized by dry mouth (xerostomia), dry eyes (keratoconjunctivitis sicca); other organs may be affected, including CNS and PNS, skin, and mucosal surfaces of upper airways, vagina, lungs, and kidneys. The primary pathology is lymphocytic infiltration of exocrine glands.
Primary Sjogren's syndrome: Condition occurs in the absence of other known inflammatory disorders.
Secondary Sjogren's syndrome: Condition occurs in the presence of defined connective tissue disease (RA, SLE, scleroderma, PM, or other autoimmune disorder).
San Diego criteria for diagnosis of both primary and secondary Sjogren's syndrome (1986):
Primary Sjogren's Syndrome
Symptoms and objective signs of ocular dryness
Schrimer's test <5 mm wetting/5 min (original criteria: 9 mm/5 min) and
Positive rose bengal or fluorescein staining of cornea or conjunctiva to demonstrate keratoconjunctivitis sicca
Symptoms and objective signs of dry mouth
Decreased parotid flow using Lashley cups
Abnormal minor salivary gland biopsy (focus score of 2 or more on average of 4 evaluable lobules; 1 focus = 50 lymphs/4 mm2)
Evidence of systemic autoimmune disorder
Elevated rheumatoid factor
Elevated ANA >1:160
Presence of SS-A (Ro) or SS-B (La). The latter has a more specific association with Sjogren's syndrome.
SSA and SSB:
Antibodies against SSA/Ro are found in approximately 50% - 80% of patients with the primary Sjogren syndrome and in 15% of patients with secondary Sjögren syndrome). Thus, the absence of anti-SSA/Ro antibodies does not eliminate the diagnosis of primary or secondary Sjögren syndrome.
Antibodies against SSA/Ro are present in 50% of patients with SLE and are sometimes found in healthy individuals. Thus, the presence of antibody against SSA/Ro cannot by itself be used to establish a diagnosis of Sjögren syndrome.
Antibodies against SSB/La are present in 40-50% of patients with primary Sjögren syndrome and in 15% of patients with SLE.- anti-La/SSB has higher specificity. Finding antibodies against SSB/La in patients without antibodies against SSA/Ro is unusual, but this combination has occurred in patients with primary biliary cirrhosis and autoimmune hepatitis.
Titers of anti-SSA/Ro and anti-SSB/La antibodies do not reflect disease activity. Current enzyme-linked immunosorbent assay tests for these antibodies are more sensitive than previous tests. Thus, the specificity is lower.
Antibodies against SSA/Ro are also associated with the annular erythematous lesions of subacute cutaneous lupus. They are also found in the mothers of newborns with neonatal lupus syndromes and congenital heart block, and some of these mothers have or will develop Sjögren syndrome.
Autoantibodies to the human muscarinic acetylcholine receptor of the M3 type (hmAchR M3) have been suggested to elevated in Sjogren syndrome.
Three novel autoantibodies (Secretory Protein-1 (SP-1), Carbonic Anhydrase-6 (CA-6) and Parotid Secretory Protein (PSP) have been identified that may aid in early diagnosis of SS.
The novel antibodies salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA VI) and parotid secretory protein (PSP) have shown to be present in animal models for Sjogren's syndrome (SS) and patients with the disease. The antibodies SP-1, CA VI and PSP occurred earlier in the course of the disease than antibodies to Ro or La. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA VI while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA VI and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La. The presence of the antibodies to SP-1, CA VI and PSP should be correlated with clinical (dry mouth, dry eyes), serological (Ro, La, ANA, RF) and histological (positive lymphocytic focus scores) findings in establishing a definitive diagnosis for SS.
Shen, L. et al. (2010). A role of lymphotxin in primary sjogren's syndrome. J Immunol 185: 6355-6363.
Shen, L. et al. (2012). Novel autoantibodies in Sjogren's syndrome. Clinical Immunology 145, 251-255.
Secondary Sjogren's Syndrome
Secondary Sjogren's Syndrome
Symptoms and signs of Sjogren's as defined above plus diagnosis of RA, SLE, scleroderma, polymoyositis, PBC (primary biliary cirrhosis), and cryoglobulinemia.
Exclusions: sarcoidosis, lymphoma, AIDS, hepatitis, known other causes of sicca, salivary gland enlargement, or autonomic neuropathy
Definite: All criteria for primary Sjogren's syndrome and lack of exclusions in secondary Sjogren's syndrome
Probable: All criteria excepts biopsy
Clinical features:
>90% of patients are women; mean age of diagnosis is 50 years, but even children, adolescents, and young adults can be affected.
Sicca complex defines the disorder:
Keratoconjunctivitis sicca (dry eyes)
Producing the classical complaint of foreign body sensation in the eye.; red eyes (less specific); corneal ulcers (severe cases)
Xerostomia (dry mouth)
Difficulty swallowing food. Adherence of food to buccal surfaces.
Frequent feeling of thirst
Dental caries > tooth loss, Halitosis, oral candidiasis,
Oral candidiasis
Recurrent or chronic episodes of major salivary gland enlargement
Recurrent parotid enlargement may be symmetrical and may be accompanied by fever, tenderness, or erythema.
Xerosis (cutaneous sicca)
Vagnitis sicca
Dryness of mucosa (nasopharynx and URI)
Extraglandular sites of involvement: PM, lungs, GIT, GUT, and even thyroid gland: Xerosis, arthralgia, autoimmune thyrodiditis, hypergammaglobulinemia, lymphopenia, PFT abnormalities, ILD, interstitial nephritis, monoclonal gammopathy, cryoglobulinemia, lymphoma, cutaneous vasculitis.
Regional lymphadenopathy may be a striking feature in some cases.
Increased levels of serum and urinary paraproteins and cryoglobulins.
CNS complications may simulate MS on MRI with multiple regions of increased signal intensity, predominantly within the subcortical and periventricular white matter.
Peripheral Nerve Complications of Sjogren's Syndrome:
Patients with Sjögren syndrome can develop a wide array of peripheral nervous system manifestations, including distal symmetric polyneuropathy, mononeuritis multiplex, sensory and autonomic neuropathy, trigeminal mononeuropathies, and a dorsal root ganglionopathy. It is suggested PNS involvement in Sjogren syndrome is ~16%, while CNS manifestations is ~4%.
Patients with SFN associated with Sjogren syndrome typically present with asymmetric dysesthetic pain and decreased pinprick and temperature in either lenght-dependent on non-length-dependent patterns. Strength and reflexes are preserved. Onset is subacute to indolent, but some patients can progress more rapidly.
Evaluation for Sjögren syndrome should be performed even in the absence of sicca syndrome if the suspicion is high, as the neuropathy may precede sicca syndrome. Serum antibodies may be negative as well; thus, minor salivary gland biopsy is recommended in patients with clinical syndromes strongly suggestive of Sjögren syndrome, including a significant sensory neuropathy and autonomic neuropathy or a dorsal root ganglionopathy.
Sensorimotor neuropathy
Distal axonal PN is the commonest type of pSS-related PN is distal axonal PN (length-dependent), accounting for almost 80% of patients with pSS-related large fiber PN. The clinical symptoms vary and depend on the type of fibers that are involved. Pain, resulting from Aδ and C fiber involvement, is usually burning and can be associated with allodynia. Pain is usually worse at night and at rest; however, paroxysmal attacks can occur during the day. Pain can be very disabling and interfere with mobility. Large fiber involvement manifests with diminished proprioception, tingling, pins and needles sensation, and numbness. Patients with more severe neuropathy may suffer from motor symptoms including muscle weakness, atrophies, and cramps.
Autonomic dysfunction includes Adie's pupils, anihdoris, compensatory segmental hyperhidrosis, GI dysmotility, and orthostatic changes in BP. Objective testing of autonomic function has yielded varying degrees of decreased cardiovagal function, impaired sympathetic vasomotor activity, or tachycaric responses to head-up tilt. Autonomic features may precede the diagnosis of Sjogren syndrome. The pathology is of autonomic dysfunction in Sjogren syndrome is thought to be related to immune mediated small fiber neuropathy affecting autonomic nerves. Some patient respond to immunotheraphy.
In a retrospective cohort study, Jamilloux et al. demonstrated that cryoglobulinemia is a unique predictive factor for developing neurological manifestations, in particular sensorimotor neuropathies and mononeuritis multiplex. Similarly, Sène et al. found a strong association between sensorimotor neuropathies and presence of mixed cryoglobulins, suggesting that vasculitis is a possible pathogenetic mechanism for pSS-related PN.
EDX demonstrate an axonal neuropathy.
Nerve biopsy may show small-vessel perivasculitis or vasculitis
Nerve fiber loss may be random or multifocal.
Treatment:
A number of treatments have been used, including plasma exchange, IVIg, rituximab, corticosteroids, cyclophosphamide, and azathioprine. One protocol proposes treating with IVIg (2 g/kg divided over 5 days) followed by monthly infusions.
For dry mouth: Biotene. Flinnts mints
Ataxic sensory neuropathy (neuronopathy)
Occurs most often in women.
Neuropathy with prominent kinesthetic loss.
Dysesthesias or paresthesia involve face, trunk, and limbs.
Severely affected individuals demonstrate pseudoathetosis of the upper limbs, with an inability to localize the limb in space.
Small fiber functions of pain and temperature are less affected.
Muscle strength preserved but loss of muscle stretch reflexes.
Progression may be indolent or rapidly progressive.
SNAPs are absent in most clinically affected limbs.
Motor nerve conduction studies are normal.
Needle EMG is normal or show minimal denervation potentials.
Nerve biopsy shows loss of myelinated nerve fibers: perivascular inflammation may be present.
No proven treatment but progression may stop and functional improvement may occur.
MRI of the spine can show T2 hyperintensity along the dorsal columns thought to be secondary to sensory ganglia neuron injury, corresponding with pathologic studies demonstrating lymphocyte infiltration of the dorsal root ganglia in affected patients
CIDP is very rarely associated with Sjogren syndrome. It is possible that these isolated cases represent a predisposition to autoimmune disease rather than a direct manifestation of the disease.
Myopathy is uncommon in Sjögren syndrome. Up to 10% of patients with inclusion body myositis have Sjögren syndrome, suggesting a potential link.
Cranial neuropathies have been reported in Sjögren syndrome with the trigeminal nerve being most frequently involved.
Mononeuritis multiplex is very uncommon and tends to occur in the setting of active systemic disease in association with vasculitic involvement of other organs, such as glomerulonephritis or palpable purpura. Low C4 levels, hypergammaglobulinemia, and cryoglobulinemia may be present. Nerve biopsy may be needed in these cases to confirmthe presence of vasculitis.
Treatment: No randomized placebo-controlled trials of immunotherapies in Sjögren syndrome have been conducted. Small fiber neuropathies aremanaged primarily symptomatically, although some patients have reported improvement with IV immunoglobulin (IVIg). Symptomatic management is also usually used in axonal sensorimotor neuropathy, although a response to immunotherapy has been reported. Dorsal root ganglionopathy tends to be refractory to immunotherapy. Mononeuritis multiplex with documented vasculitis is treated with high-dose corticosteroids, rituximab, or cyclophosphamide.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8205474/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10087501/
https://www.mdpi.com/2077-0383/9/7/2299
Modern Rheumatology, Volume 19, Issue 4, 1 August 2009, Pages 437–440, https://doi.org/10.3109/s10165-009-0180-2
Intravenous immunoglobulin
Intravenous immunoglobulin
Ιn a retrospective multicenter study, the efficacy and tolerance of IVIG was investigated in 19 patients with pSS-related neuropathy without necrotizing vasculitis. All patients were initially treated with monthly IVIG, at a dose of 2 g/kg body weight over either 2 or 5 days. IVIG treatment was well tolerated, and half of the patients improved. Patients with sensorimotor neuropathies or nonataxic sensory neuropathy had the best response. In a cross-sectional study by Mori et al., 13 patients with pSS-related neuropathy were treated with IVIG at a dose of 2 g/kg body weight over 5 days.
Patients with polyradiculoneuropathy and painful sensory neuropathy showed the most favorable response, whereas patients with sensory ataxic neuropathy had a less favorable response. In a retrospective cohort study by Pereira et al., IVIG was administered in a small number of pSS patients with sensory ganglionopathy (n = 6), either as a monotherapy or as an add-on treatment, with poor results. Pindi Sala et al. recently published their experience in the use of IVIG in a series of pSS patients with pure SFN (n = 12), reporting that in 75% of patients analgesics were discontinued and in the remaining 25% of patients the need of analgesics was reduced following IVIG treatment (median duration of treatment = 21 months, range = 2–51 months). Interestingly, even in patients who had completed the IVIG treatment the benefit remained for a mean follow-up of 25 months. This suggests a long-term benefit of immunoglobulin in patients with SFN; however, a large controlled trial is needed to determine the optimal doses of immunoglobulin in SFN for initial and maintenance therapy.
Glucocorticoid monotherapy
Glucocorticoid monotherapy
Glucocorticoid therapy is the most tested intervention for the management of neuropathy attributable to pSS. In a retrospective cohort study, Terrier et al. used oral glucocorticoids (prednisone, n = 16; pulse methylprednisolone, n = 22) as a first-line treatment and found that patients with vasculitis had a better response than those without at 6 months (p < 0.001) [43]. Similarly, Mori et al. assessed pSS patients who received prednisone (at a dose of 1 mg/kg/day) for the management of neuropathy (n = 51) and found that those suffering from mononeuritis multiplex had the greatest benefit, perhaps suggesting that these patients had pSS-related vasculitis of the PNS [19]. In a prospective cohort study, oral prednisone (at a dose of 0.5–1 mg/kg/day) was examined either as monotherapy or in combination with cyclophosphamide or intravenous immunoglobulin (IVIG) in patients with pure sensory neuropathy, resulting in a clinical stabilization or improvement in most cases for a mean follow-up period of 10 years [47]. In contrast, in their retrospective cohort study, Delalande et al. found no beneficial effect of steroids in patients with axonal polyneuropathy or ganglionopathy.[
MMF, CYC..
MMF, CYC..
Immunosuppressive agents have been investigated less in the management of pSS-related neuropathy. Cyclophosphamide combined with corticosteroids was assessed in a small group of pSS patients with multiple mononeuropathy (n = 7), leading to a partial recovery or stabilization in all patients. In a retrospective cohort study, mycophenolate mofetil has been tested as an add-on to glucocorticoids in a small group of pSS patients with sensory ganglionopathy (n = 7), with good results.
Rituximab is best supported for the vasculitic/cryoglobulinemic subtype of Sjögren peripheral neuropathy.
Rituximab is best supported for the vasculitic/cryoglobulinemic subtype of Sjögren peripheral neuropathy.
The French AIR registry (Mekinian et al., Ann Rheum Dis 2012;71:84–7; DOI, PMID 21926185) showed neurological response in 9/10 (90%) of vasculitis/cryoglobulinemia patients versus 2/7 (29%) without (p=0.03) — the single most directly relevant dataset, though a registry cohort, not an RCT. PubMed
The evidence base is entirely observational (registries, retrospective cohorts, case series/reports). The two large RCTs (TEARS, TRACTISS) tested glandular/fatigue endpoints, not neuropathy, and were negative. Nonetheless, the 2025 ACR PNS guideline (Deboo et al., Arthritis Care Res; DOI) issues a STRONG recommendation for high-dose glucocorticoids + rituximab as first-line for vasculitic neuropathy — reasoning explicitly from the "risk of irreversible axonal loss and chronic disability," not from RCT efficacy data. sjogrens
Phenotype dictates rituximab candidacy. Vasculitic multiple mononeuropathy/sensorimotor axonal neuropathy and cryoglobulinemic neuropathy are the responsive phenotypes; trigeminal/cranial sensory neuropathy and pure sensory ganglionopathy/small fiber neuropathy (CD8⁺ T-cell–mediated ganglionitis) respond poorly and are not rituximab indications.
Key Findings
Key Findings
Two distinct pathophysiologies, two treatment logics. Sjögren neuropathy splits mechanistically into (a) a vasculitic process of the vasa nervorum (epineurial microvessels) causing ischemic axonal loss — the substrate of multiple mononeuropathy and much vasculitic sensorimotor polyneuropathy; and (b) a T-cell–mediated dorsal-root/trigeminal ganglionitis (ganglionopathy/neuronopathy) plus small fiber neuropathy. Rituximab (anti-CD20/B-cell) has mechanistic and empirical rationale in the former — especially with cryoglobulinemia — and performs poorly in the latter.
The pivotal dataset is the AIR registry. In 17 pSS patients with PNS involvement, response at 3 months was 9/10 (90%) in the vasculitis/cryoglobulinemia group versus 2/7 (29%) without (p=0.03), with significant Rankin and ESSDAI improvement in the vasculitis group. Level of evidence: prospective registry cohort. PubMed
Cranial (trigeminal) neuropathy is usually NOT vasculitic and generally not a rituximab target; it more often belongs to the ganglionopathic spectrum. Mori's clinicopathological classification links trigeminal and sensory ataxic/painful sensory neuropathy to a ganglioneuronopathic process, and multiple mononeuropathy/multiple cranial neuropathy to a vasculitic process. PubMed
Comparators. Cyclophosphamide (± glucocorticoids) is the historical standard for vasculitic/mononeuritis-multiplex disease; IVIG helps sensorimotor and non-ataxic sensory neuropathy but is unreliable in ataxic/ganglionopathic disease and is explicitly not first-line for vasculitic neuropathy in the 2025 ACR guideline; glucocorticoids benefit mononeuritis multiplex most. PubMed
Dosing is extrapolated, not neuropathy-specific. Two conventions dominate: lymphoma/ANCA-vasculitis induction (375 mg/m² weekly ×4) and the rheumatoid-arthritis convention (1000 mg ×2, two weeks apart). The Sjögren neuropathy literature uses both; no head-to-head trial exists in this indication. mcp__PubMed__get_article_metadata
Details
Details
1. Pathophysiology of vasculitic nerve involvement in Sjögren
1. Pathophysiology of vasculitic nerve involvement in Sjögren
Peripheral nerve vasculitis affects the 50–300 µm epineurial vessels of the vasa nervorum; because of rich anastomotic supply, ischemic axonal damage occurs only after extensive microvascular involvement, producing asymmetric, fascicle-to-fascicle axonal loss with myelinated fibers more vulnerable than unmyelinated. The classic description by Peyronnard et al. (Neurology 1982;32:839; two rheumatoid, one Sjögren patient) documented axonal neuropathy with occlusion of the vasa nervorum and vasculitic involvement of epineurial vessels in all patients, noting potential for recovery because Schwann cells tolerate ischemia better than axons. Biopsy in vasculitic neuropathy shows epineurial perivascular and transmural inflammatory infiltrate (predominantly lymphocytic in most secondary vasculitides); "definite" vasculitis (Peripheral Nerve Society criteria) requires inflammatory cells within the vessel wall plus vascular damage (fibrinoid necrosis, endothelial disruption, internal elastic lamina fragmentation), while "probable" relies on perivascular inflammation with asymmetric/sectorial fiber loss. PubMed CentralSage Journals
An immunohistochemically detailed sural-nerve biopsy study of pSS-associated peripheral neuropathy ("Macrophage 2 plays an important role in axonal lesions and vasculitis in Sjögren's syndrome complicated with peripheral neuropathy") demonstrated infiltration of CD68⁺ macrophages — predominantly of the M2 phenotype — around small vessels and within nerve bundles, with electron microscopy showing macrophages stripping myelin and inflammatory infiltration of the vasa nervorum causing blood-cell stasis, endothelial damage, platelet aggregation, and vascular obstruction; the authors concluded that vasculitic peripheral neuropathy is the predominant form of pSS-PN and proposed M2 macrophages as a pathogenic driver.
By contrast, the sensory ganglionopathy of Sjögren is driven by CD8⁺ cytotoxic T-cell infiltration of the dorsal root ganglia with neuronal loss — a fundamentally T-cell (not B-cell) process, explaining rituximab's weaker performance there. Mori et al. (Brain 2005;128:2518–34; DOI, PMID 16049042), the foundational 92-patient clinicopathological series, classified Sjögren neuropathy into seven forms — sensory ataxic (n=36), painful sensory without ataxia (n=18), multiple mononeuropathy (n=11), multiple cranial neuropathy (n=5), trigeminal (n=15), autonomic (n=3), and radiculoneuropathy — and found angiitis/perivascular cell invasion most frequent in multiple mononeuropathy, followed by sensory ataxic neuropathy, while multifocal T-cell invasion appeared in dorsal-root/sympathetic ganglia, perineurial space, and vessel walls. Their interpretive conclusion — sensory ataxic, painful, and perhaps trigeminal neuropathy reflect a ganglioneuronopathic process, whereas multiple mononeuropathy and multiple cranial neuropathy are more closely vasculitic — is the backbone of phenotype-driven treatment selection. Practical Neurology + 3
2. Evidence for rituximab in the vasculitic subtype
2. Evidence for rituximab in the vasculitic subtype
AIR registry (Mekinian 2011/2012) — the most directly relevant analysis: 90% (9/10) response in vasculitis/cryoglobulinemia vs 29% (2/7) without (p=0.03); Rankin and ESSDAI improved significantly in the vasculitis group. Prospective registry cohort. PubMed
Gottenberg et al., AIR registry (Ann Rheum Dis 2013;72(6):1026–31): 78 pSS patients (74 with systemic involvement); 60% responded to the first rituximab cycle, with median ESSDAI falling significantly from 11 (2–31) to 7.5 (0–26) (p<0.0001). Corroborates that vasculitis/sensorimotor neuropathy responds while pure sensory neuropathy does not. Retrospective/prospective registry. EularNHS England
Pepple et al., ACR Open Rheumatol 2022 (single-center repeat-cycle cohort): verbatim, "all our 7/40 patients with neurological manifestations (with or without vasculitis) responded to rituximab (sensory neuronopathy/ganglionopathy = 2; sensory-motor polyneuropathy = 2; cryoglobulinemic neuropathy = 1; cerebral vasculitis = 1; transverse myelitis = 1)." Response predictors: concomitant immunosuppressant and achieving complete B-cell depletion. Small retrospective cohort; note the small, heterogeneous neurological subgroup. Wiley
Cryoglobulinemic vasculitis: multiple positive case reports, including Sjögren-associated type II mixed cryoglobulinemic cerebral vasculitis treated successfully with rituximab (Terrier et al., Neurol Neuroimmunol Neuroinflamm 2015; DOI). Neurology
Direct RTX vs cyclophosphamide comparison: Buss R, Vital EM, Davey R, Emery P, Md Yusof MY, Rheumatology 2025;64(Suppl_3):keaf142.195 (abstract P158) — a 20-year single-centre cohort of 23 SjD-PN patients (diagnoses: pure sensory polyneuropathy/ganglionopathy 44.4%, sensorimotor axonal 33.3%, mononeuritis multiplex 11.1%, cryoglobulinaemic 11.1%). At 6 months, rituximab vs cyclophosphamide gave Complete 29% vs 0% (p=0.127) and Any Response 79% vs 56% (p=0.363) — numerically favoring rituximab but not statistically significant in a small sample. Conference abstract — lowest tier of the cohort evidence.
Level-of-evidence summary: No RCT addresses Sjögren vasculitic neuropathy specifically. Best evidence = prospective registry cohorts (AIR) + retrospective cohorts/case series/reports.
3. Trials (context; not neuropathy-powered)
3. Trials (context; not neuropathy-powered)
TEARS (Devauchelle-Pensec et al., Ann Intern Med 2014;160:233–42): 120 patients, RTX 1000 mg ×2 (weeks 0, 2); failed primary VAS endpoint.
TRACTISS (Bowman et al., Arthritis Rheumatol 2017;69:1440–50; DOI, PMID 28296257): 133 patients, RTX 1000 mg ×2 courses (weeks 0, 2, 24, 26); negative for fatigue/oral dryness, modest salivary-flow benefit; concluded rituximab "neither clinically effective nor cost-effective in this patient population."
Neither trial enrolled or powered for vasculitic neuropathy; both used the RA-type 1000 mg ×2 regimen. A post-hoc CRESS-endpoint reanalysis of TRACTISS was more favorable, but this does not bear on neuropathy.
4. Dosing protocols
4. Dosing protocols
Lymphoma/ANCA induction: 375 mg/m² IV weekly ×4 (RAVE — Stone et al., NEJM 2010;363:221; RITUXVAS — Jones et al., NEJM 2010;363:211). New England Journal of Medicine
RA / Sjögren-trial convention: 1000 mg IV ×2, two weeks apart (TEARS, TRACTISS); equivalent B-cell depletion and remission to the 4-dose regimen in AAV (Jones 2009; single-dose 375 mg/m² also shown reasonable/cost-effective in AAV).
Cryoglobulinemic vasculitis: both regimens reported.
The 2025 ACR PNS guideline names rituximab as first-line for vasculitic neuropathy but does not specify a numeric dosing regimen in its accessible recommendation statements. In practice, clinicians extrapolate an ANCA-vasculitis regimen, co-prescribe an immunosuppressant + glucocorticoids, and add maintenance where cryoglobulinemia is present.
5. Comparison with other agents
5. Comparison with other agents
Cyclophosphamide: historical first-line for Sjögren mononeuritis multiplex/vasculitic neuropathy; response reported as high (up to ~100% in mononeuritis multiplex in some series). The PNS Society NSVN guideline (Collins et al., J Peripher Nerv Syst 2010;15:176–84; DOI, PMID 21040139) recommends corticosteroid monotherapy ≥6 months first-line, combination therapy for rapidly progressive/refractory disease, cyclophosphamide (IV pulses preferred to limit cumulative dose) for severe neuropathy, and azathioprine/methotrexate maintenance for 18–24 months.
IVIG: Rist et al. (Arthritis Care Res 2011;63(9):1339–44; PMID 21584943), 19 pSS neuropathy patients without necrotizing vasculitis — verbatim, "All the patients with sensorimotor (n=5) or nonataxic sensory neuropathy (n=4) were improved or stabilized... among the patients with ataxic neuropathy (n=9), only 2 improved and 4 worsened"; overall 9/19 (47%) improved by physician global. IVIG is thus positioned for non-vasculitic large-fiber/sensorimotor and non-ataxic sensory disease. PubMed
Mycophenolate / azathioprine / methotrexate: steroid-sparing/maintenance roles; limited data (e.g., MMF add-on in small ganglionopathy series).
Positioning: rituximab and cyclophosphamide are the aggressive options for vasculitic/cryoglobulinemic disease; IVIG for non-vasculitic sensorimotor/non-ataxic sensory; symptomatic-only for pure SFN/ganglionopathy per EULAR (Ramos-Casals et al., Ann Rheum Dis 2020;79:3–18).
6. Cranial vs peripheral vasculitic patterns and rituximab candidacy
6. Cranial vs peripheral vasculitic patterns and rituximab candidacy
The literature consistently separates:
Trigeminal/cranial sensory neuropathy — common in Sjögren (Mori: trigeminal n=15, ~16% of series; ~16% trigeminal in a 92-patient series), typically part of the ganglionopathic spectrum, often chronic and not vasculitic; not a rituximab indication. The 2025 ACR guideline recommends short-course oral glucocorticoids for suspected acute inflammatory trigeminal neuropathy and carbamazepine/oxcarbazepine (then gabapentin/pregabalin/lamotrigine/lacosamide) for trigeminal neuralgia — not rituximab. Isolated case reports (e.g., Sève et al., Rheumatol Int 2007;28:175–7, mental-nerve/numb-chin syndrome; DOI, PMID 17641898) describe rituximab benefit, but these are anecdotal and conflict with cohort data.
Multiple cranial neuropathy — in Mori's schema more closely vasculitic, and thus a more plausible rituximab candidate when a vasculitic mechanism is demonstrated.
Peripheral vasculitic mononeuritis multiplex / vasculitic sensorimotor polyneuropathy — the archetypal rituximab-responsive phenotype, especially with cryoglobulinemia.
Diagnostic red flags for vasculitis (favoring aggressive immunotherapy including rituximab), per the 2025 ACR "Good Practice" statements: acute/painful/rapid or stepwise deficits; clinical and EMG evidence of multiple mononeuropathies; single-organ or systemic vasculitis; and immunologically active disease (cryoglobulinemia, hypocomplementemia, monoclonal gammopathy, positive RF, elevated inflammatory markers). Nerve ± muscle biopsy is warranted when a vasculitic etiology is suspected.
Recommendations
Recommendations
Staged approach for a Sjögren patient with suspected vasculitic neuropathy:
Confirm the phenotype first. Distinguish vasculitic (asymmetric, painful, stepwise, multiple mononeuropathy, motor involvement, cryoglobulin/complement/RF abnormalities) from ganglionopathic/small-fiber disease (non–length-dependent sensory loss, ataxia, preserved strength). Pursue nerve ± muscle biopsy when vasculitis is suspected and the diagnosis is uncertain; obtain cryoglobulins, C4, RF, SPEP/immunofixation.
If vasculitic neuropathy is confirmed or high-suspicion: initiate high-dose glucocorticoids + rituximab as first-line (2025 ACR guideline, Deboo et al., Arthritis Care Res; DOI — STRONG recommendation; the guideline states "Because rituximab has a generally lower risk of adverse events than cyclophosphamide, it is recommended as a first-line treatment for vasculitic neuropathy," rated strong "because, given the risk of irreversible axonal loss and chronic disability, most physicians and patients would opt for initial immune therapy"). Extrapolate an ANCA-vasculitis rituximab regimen (375 mg/m² weekly ×4 or 1000 mg ×2 at two weeks); co-prescribe an immunosuppressant and aim for complete B-cell depletion (cohort predictor of sustained response). Wiley
If refractory to glucocorticoids + rituximab: switch to glucocorticoids + cyclophosphamide (2025 ACR — CONDITIONAL, second-line; IV pulse preferred per PNS Society NSVN guidance). sjogrens
If cryoglobulinemia is present: plan maintenance immunomodulatory therapy and follow cryoglobulins, C4, and RF as biological response markers (2025 ACR — CONDITIONAL / Good Practice).
Do NOT use IVIG first-line for vasculitic neuropathy (2025 ACR — CONDITIONAL against); reserve IVIG for non-vasculitic sensorimotor/non-ataxic sensory neuropathy. sjogrens
For trigeminal/cranial sensory neuropathy: do not default to rituximab; use short-course glucocorticoids if acute inflammatory, and neuropathic-pain agents (carbamazepine/oxcarbazepine) — unless a vasculitic mechanism (e.g., multiple cranial neuropathy) is demonstrated.
For pure SFN/ganglionopathy: symptomatic management first; immunotherapy (glucocorticoids + immunomodulatory agent; IVIG for SFN; rituximab reserved for refractory autonomic disease after IVIG in the 2025 ACR schema) reserved for severe/progressive disease with acknowledged uncertain benefit. sjogrens
Thresholds that change management: biopsy-proven necrotizing vasculitis or cryoglobulinemia escalates toward rituximab/cyclophosphamide; a pure ganglionopathic/small-fiber phenotype de-escalates away from rituximab toward symptomatic care ± IVIG trial. Failure to achieve complete B-cell depletion, or secondary non-depletion/non-response on repeat cycles, should prompt reconsideration of the agent.
Caveats
Caveats
No RCT exists for rituximab in Sjögren vasculitic neuropathy; the strongest evidence is a single registry subgroup (10 vasculitis/cryo patients in AIR) plus retrospective cohorts and case reports — inherently subject to selection and publication bias. The strongest RTX-vs-CYC comparison (Buss/Md Yusof 2025) is a conference abstract and statistically non-significant.
The 2025 ACR STRONG first-line recommendation for glucocorticoids + rituximab rests on expert consensus and risk-of-harm reasoning (irreversible axonal loss), not high-certainty efficacy data; certainty of evidence is low. The guideline uses a two-tier STRONG/CONDITIONAL (GRADE-based) scale.
"Response" definitions vary (modified Rankin, ESSDAI, physician global) and are not neuropathy-specific validated endpoints; cross-study comparison is imprecise.
Case reports of rituximab benefit in trigeminal/small-fiber neuropathy exist but conflict with cohort data showing poor response in non-vasculitic phenotypes; these should not drive practice.
Dosing in this indication is entirely extrapolated from AAV/RA/lymphoma; the optimal regimen and maintenance strategy for Sjögren vasculitic neuropathy are undefined. A specific numeric rituximab regimen was not stated in the accessible 2025 ACR guideline recommendation text.
Seronegative and biopsy-diagnosed (focus score ≥1) Sjögren patients appear across these series; anti-Ro/SSA positivity is common (~48–83% across cohorts) but not universal, so seronegativity should not exclude the diagnosis when sialadenitis is documented.
The therapeutic landscape may shift: the 2025 ACR guideline task force noted emerging late-phase data for other B-cell-targeted agents in Sjögren's (e.g., ianalumab, telitacicept), which could alter positioning of anti-CD20 therapy in future.
The classification of Sjögren syndrome applies to any individual who meets the inclusion criteria, does not have any of the conditions listed as exclusion criteria, and has a score of 4 or more when the weights from the five criteria items below are summed.
These inclusion criteria are applicable to any patient with at least one symptom of ocular or oral dryness, defined as a positive response to at least one of the following questions:
Have you had daily, persistent, troublesome dry eyes for more than 3 months?
Do you have a recurrent sensation of sand or gravel in the eyes?
Do you use tear substitutes more than 3 times a day?
Have you had a daily feeling of dry mouth for more than 3 months?
Do you frequently drink liquids to aid in swallowing dry food? or to any patient in whom there is suspicion of Sjögren syndrome from the European League Against Rheumatism Sjögren Syndrome Disease Activity Index questionnaire (at least one domain with a positive item).
Exclusion criteria include prior diagnosis of any of the following conditions, which would exclude diagnosis of Sjögren syndrome and participation in Sjögren syndrome studies or therapeutic trials because of overlapping clinical features or interference with criteria tests: history of head and neck radiation treatment, active hepatitis C infection (with confirmation by polymerase chain reaction [PCR]), acquired immunodeficiency syndrome (AIDS), sarcoidosis, amyloidosis, graft versus host disease, or IgG4-related disease.
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome
The final classification criteria are based on the weighted sum of five items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm2, each scoring 3; an abnormal Ocular Staining Score of ≥5 (or van Bijsterveld score of ≥4), a Schirmer's test result of ≤5 mm/5 min and an unstimulated salivary flow rate of ≤0.1 mL/min, each scoring 1. Individuals with signs and/or symptoms suggestive of SS who have a total score of ≥4 for the above items meet the criteria for primary SS. Sensitivity and specificity against clinician-expert—derived case/non-case status in the final validation cohort were high, that is, 96% (95% CI92% to 98%) and 95% (95% CI 92% to 97%), respectively.
The minor salivary gland (MSG) tissue can be diagnostically examined by using the focus score (FS) which describes the number of cell infiltrates of at least 50 mononuclear cells within 4 mm2 (i.e., a focal infiltrate).
The focus score (J Rheumatol. 2002;29(5):938-44) is: less than 1 per 4 mm squared.
N.B.: Focus scores greater than one histologically support a diagnosis of Sjogren syndrome (Oral Maxillofac Surg Clin North Am. 2014;26(1):13-22). Therefore, the histologic findings DO NOT support a diagnosis of Sjogren syndrome in this patient; however, Sjogren syndrome cannot be ruled out based on histologic findings alone, due to sampling error. The findings have been correlated with the results of serology studies, available in the patient's electronic medical record (EPIC) at the time of sign out. A review of the patient's medication list as available in EPIC may be of merit.
A focus has been defined as 50 or more lymphocytes or plasma cells or both lobules are included in this biopsy; a biopsy of five or more lobules is recommended.
In practice however any 3 out of 4 criteria is used for the diagnosis of Sjogren syndrome:
Objective evidence of dry eyes.
Objective evidence of dry mouth.
Anti-SSA positivity.
Focal lymphocytic sialadenitis with a focus score of at least or more than 1/4 mm2
Case 1:
Case 1:
BX is a 62 y.o. female who came to rheumatology clinic for follow up evaluation of Sjogrens. Patient was previously diagnosed with Sjogrens (sicca symptoms and neuropathy) because of lip biopsy that was consistent with Sjogrens and +SSA. Patient was previously on Plaquenil but stopped due to visual concerns. This was more a personal preference rather than a direct contraindication from ophthalmology. However patient felt while she was on Plaquenil 200 mg daily it was not helping either her neuropathy or Sicca symptoms. Currently she is not on any immunosuppressive therapy for Sjogren's. She manages Sicca symptoms conservatively. Follows with neurology for small fiber neuropathy and is currently on gabapentin. Neurology is considering repeat EMG/NCS to ascertain polyneuropathy. Will repeat serology workup. In the future if neuropathy symptoms worsen or become uncontrolled, Sicca symptoms get worse, inflammatory joint pain arises can consider reintroduction of Plaquenil or discuss other potential immunosuppressive agents. For now we will maintain off any immunosuppressive therapy.
Google Sites
Report abuse